1.Literature Analysis of 66 Cases of Drug-induced Hyperkalemia
Xiaolei REN ; Yiqiu ZHAN ; Chunyan ZHANG ; Haiying ZHANG ; Wanyu FENG
China Pharmacy 2015;(20):2790-2792
OBJECTIVE:To investigate the characteristics and related factors of drug-induced hyperkalemia,present preven-tive measures and provide reference for the rational drug use. METHODS:46 literatures of individual cases and group cases of drug-induced hyperkalemia publicly reported in domestic medical journals from 1979 to 2014 were collected and analyzed statistical-ly,including 66 cases. RESULTS:66 cases with drug-induced hyperkalemia were mainly involved in cardiovascular drugs and im-munosuppressants. Most of them were improved after drug withdrawal and symptomatic treatment,and 2 cases died. CONCLU-SIONS:Drug-induced hyperkalemia are potentially dangerous. It is necessary to be vigilant,prevent and control timely and reduce the incidence of severe adverse reactions.
2.Efficacy and Safety of Alprostadil Injection in Treatment of Viral Hepatitis:A Meta-analysis
Xiaolei REN ; Yiqiu ZHAN ; Zhen HE ; Haiying ZHANG ; Chunyan ZHANG ; Wanyu FENG
Herald of Medicine 2017;36(6):687-691
Objective To systematically evaluate the efficacy and safety of alprostadil injection in patients with viral hepatitis.Methods Medline,Embase,The Cochrane Library,CBMdisc,CNKI,Wanfang Database and VIP were searched.The quality of included studies such as randomization,blinding,allocation concealment and loss of follow-up were evaluated and meta-analysis was performed by RevMan5.1 software.Results In total,14 RCTs and 1 232 patients were included.Meta-analysis showed that in patients with viral hepatitis,the total effective rate of alprostadil injection treatment was significantly superior to that of conventional therapy (P<0.000 01).Serious adverse drug reactions (ADRs) induced by alprostadil injection were not reported.Conclusion Alprostadil injection is effective and safe for treating viral hepatitis.However,the evidence is not strong due to the generally low methodological quality of RCTs.Further high quality and large sample-sized randomized controlled trials and more pharmacoeconomics studies should be carried out.
3.Rapid Health Technology Assessment for Effectiveness ,Safety and Economics of Ginkgo biloba Extract in the Treatment of Alzheimer ’s Disease
Xiaolei REN ; Yi LIU ; Yiqiu ZHAN ; Chunyan ZHANG ; Lin HUANG ; Yufei FENG
China Pharmacy 2020;31(22):2786-2790
OBJECTIVE:To rapidly evaluate the effectiveness ,safety and economics of Ginkgo biloba extract(EGb)in the treatment of Alzheimer ’s disease (AD)patients,and to provide evidence-based reference for clinical drug selection and decision. METHODS:Retrieved from PubMed ,Embase,Cochrane Library ,Web of Science ,CNKI,CBM,Wanfang database ,health technology assessment (HTA)organization websites and database during the inception to Aug. 10,2020,HTA reports ,systematic reviews/Meta-analysis,and pharmacoeconomic studies of EGb versus placebo in the treatment of AD were collected. After literature screening and data extration ,HTA checklist ,AMSTAR-2 scale and CHEERS scale were used respectively to evaluate the literature quality of the included HTA report ,systematic review/Meta-analysis and pharmacoeconomics studies. The conclusion of the included studies were summarized by using qualitative description. RESULTS :A total of 9 literatures were included ,involving 8 systematic reviews and 1 economic studies. In terms of effectiveness ,there was no statistical significance in MMSE score of EGb group,ADAS-Cog score of 120 mg EGb group ,compared with placebo group (P>0.05). Dementia Quality of Life (DQoL)score of EGb group was significantly higher than that of placebo group. The scores of short cognitive aptitude tests ,neuropsychiatric inventory(NPI),NPI caregiver version score ,ADAS-Cog score of 160 mg EGb group and 240 mg EGb group were significantly lower than those of control group (P<0.05). ADL scores of patients were inconsistent ;ADL scores of EGb group were significantly lower than those o f placebo group (P<0.05),or there was no significant diff erence between 2 groups(P>0.05); . subgroup analysis by dose showed that there was no RDY2019-39) significant difference in ADL score between 120 mg EGb group and placebo group (P>0.05);ADL score of 240 mg E-mail:renxiaolei83@126.com EGb group were signicantly lower than that of placebo group (P<0.05). Subgroup analysis of clinical global impression 010-88325751。E-mail:lyi1267@126.com change (CGIC) score showed that there was no significant difference in CGIC score between EGb group and placebo group after receiving <200 mg EGb and 26 weeks of treatment (P> 0.05);CGIC score of EGb group was significantly higher than that of placebo group after receiving >200 mg EGb and 24 weeks of treatment (P<0.05). In terms of safety ,there was no statistical significance in the incidence of ADR or the incidence of severe ADR between EGb group and placebo group (P>0.05). Subgroup analysis by dose showed that the incidence of ADR in 240 mg EGb group was significantly higher than placebo group (P<0.05). Economically ,EGb treatment for AD is cost-effective ,which could indirectly save the nursing costs of AD patients. CONCLUSIONS :The efficacy of EGb in the treatment of AD is uncertain , and the safety and economy are good.
4.Development of SQL-based reporting tools and its application in radiotherapy workflow quality management
Jie NI ; Juying ZHOU ; Wei ZHAN ; Jian GUO ; Long CHEN ; Guanghui GAN ; Yueliang XU ; Yiqiu LI
Chinese Journal of Radiological Health 2021;30(3):309-314
Objective To effectively use the clinical data generated in daily operation and to realize information networking based on the existing resources of radiotherapy department. To improve quality management efficiency in radiotherapy process. Methods The radiotherapy process and required documents were analyzed. The reporting tool Microsoft Report Builder, which is based on SQL database, was applied to design the patient documents by extracting and analyzing a large number of data generated by Aria, the existing network of our radiotherapy department. PDCA Tools was used to analyze the weak links in the process. Reports with quantitative indices have been designed according to corresponding countermeasures, so as to improve quality control level of the process. Results More than one thousand patients were treated in our department since 2020. All patient documents of radiotherapy can be archived and inquired online after registration only once. 13 daily statistical reports, 5 quarters and 3 annual reports were scheduled according to practical demands. The waiting time before radiotherapy was shortened from 16.2 days to 14.8 days after operating the reporting system 3 months later. The staff could master the treatment progress of patients easily and patients who interrupted the treatment were found in time. Conclusion The reporting tools can realize patient information extraction and networked management effectively in radiotherapy process. Staff efficiency of personnel work and communication was improved. The resource allocation was optimized according to the report data in real time, improving the efficiency and quality of radiotherapy. This method is generally applicable and practical to radiotherapy department.